Cepheid (NASDAQ: CPHD) and Vascular Solutions (NASDAQ:VASC) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends.

Volatility & Risk

Cepheid has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Vascular Solutions has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Cepheid and Vascular Solutions, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cepheid 0 10 0 0 2.00
Vascular Solutions 0 4 0 0 2.00

Cepheid currently has a consensus price target of $48.00, indicating a potential downside of 9.35%. Vascular Solutions has a consensus price target of $55.50, indicating a potential downside of 0.89%. Given Vascular Solutions’ higher possible upside, analysts plainly believe Vascular Solutions is more favorable than Cepheid.

Valuation and Earnings

This table compares Cepheid and Vascular Solutions’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Cepheid N/A N/A N/A ($0.69) -76.74
Vascular Solutions N/A N/A N/A $0.70 80.00

Cepheid is trading at a lower price-to-earnings ratio than Vascular Solutions, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

95.8% of Cepheid shares are owned by institutional investors. Comparatively, 80.2% of Vascular Solutions shares are owned by institutional investors. 4.2% of Cepheid shares are owned by company insiders. Comparatively, 6.9% of Vascular Solutions shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Cepheid and Vascular Solutions’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cepheid -6.88% -11.54% -5.18%
Vascular Solutions 13.02% 15.78% 14.30%

Summary

Vascular Solutions beats Cepheid on 7 of the 8 factors compared between the two stocks.

Cepheid Company Profile

Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company’s systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to Deoxyribonucleic acid (DNA) amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.

Vascular Solutions Company Profile

Vascular Solutions, Inc. is a medical device company focused on bringing clinically advanced solutions to the market for treating coronary and peripheral vascular disease. The Company’s product line consists of devices and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists and vein practices around the world. Its products include GuideLiner catheters, Pronto catheters, Vein catheter reprocessing, Micro-introducer kits, Hemostatic patches, Radial access products, Langston catheters and D-Stat Flowable hemostat. The Company’s product portfolio includes a spectrum of over 90 products consisting of approximately 900 stock keeping units (SKUs) covering an array of blood clotting devices, extraction catheters, access catheters, guide extension catheters, micro-introducer kits, guidewires, snare and retrieval devices, a reprocessing service for radiofrequency catheters and a laser and procedure kits for the treatment of varicose veins.

Receive News & Stock Ratings for Cepheid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cepheid and related stocks with our FREE daily email newsletter.